Understand one of the most common concerns about clinical trial design.
A placebo is a dummy treatment that looks identical to the experimental drug but contains no active ingredient. Common placebo formulations include a sugar pill, a saline injection, or a sham device that mimics the appearance and procedure of the real intervention. The placebo is designed to be indistinguishable from the active drug so that participants and researchers cannot tell which group a patient is in.
Placebos exist because many people feel better simply from the act of being treated. This is called the placebo effect, and it can be substantial. In a review of 73 irritable bowel syndrome trials, about 27% of people who got a placebo said their overall symptoms improved. How large the effect is depends on the condition and on how improvement is measured.
Many patients worry about getting a placebo, and that concern deserves a clear answer. Yes, placebos are sometimes used. The question is when, why, and how to evaluate whether a placebo-controlled trial makes sense for your specific situation.
Researchers use placebos to separate the actual pharmacologic effect of a drug from the psychological effect of receiving treatment. Without a placebo group, a trial cannot reliably distinguish between drug response and the natural fluctuation of disease, the regression-to-the-mean phenomenon, or the well-documented placebo response itself.
The FDA requires evidence from well-controlled studies before approving a new drug. Under federal rules, the comparison group can be a placebo, a different dose, no treatment, an existing drug, or in special cases a historical control such as patients followed in a natural history study. Without controlled comparison, regulators cannot confirm that the drug actually drives the observed improvement, especially in conditions where natural recovery rates or symptom variability are high.
The placebo effect is real and measurable. Brain imaging studies have shown that a placebo can trigger the release of the body's own natural painkillers and of dopamine, a brain chemical linked to reward. This is not imagined improvement. The placebo group helps researchers isolate which improvements come from the drug itself and which would have happened with any treatment.
The probability of receiving placebo varies dramatically by trial design. The randomization ratio determines the odds, and it is one of the most important questions to ask the trial coordinator before enrolling. Rare disease trials are more likely than other trials to give every participant the study drug.
Some trials split participants evenly, so you have a 50% chance of placebo. Others put more people on the study drug, for example 2 out of every 3 or 3 out of every 4. Many rare disease trials are open-label, meaning everyone receives the study drug and there is no placebo group.
Crossover designs guarantee that every participant receives the active drug at some point in the trial, just at different times. In a typical crossover trial, you might receive placebo for the first 12 weeks and the active drug for the next 12 weeks (or the reverse), with washout periods in between. On ClinicalTrials.gov, the Study Design section shows whether a trial is randomized and who is blinded, and the arms list shows each group. The exact ratio is not a standard field, so ask the study team if the description does not say.
A review of 2,759 rare disease trials registered on ClinicalTrials.gov through 2012 found that 63% had only one treatment group and no comparison group, compared with 30% of trials in common conditions. There are several reasons for this. The patient pool is small, so spending half of it on placebo wastes a scarce research resource. Many rare diseases have no approved therapy, which means there is no standard of care for placebo to ethically replace. The disease is often progressive and serious, which makes withholding active treatment harder to justify under the Declaration of Helsinki ethics framework.
Look for the words "open-label" in the trial description. An open-label trial means everyone knows they are receiving the real treatment, with no placebo arm. Open-label designs are common in rare disease research. In one review, 79% of rare disease trials were open-label, compared with 52% of trials in common conditions. Sometimes a single-group trial is compared with a well-documented natural history of the disease instead of a placebo group.
Natural history studies (which document how a disease progresses without intervention) are increasingly important for rare disease drug development. In some cases, sponsors can compare treated patients with natural history data instead of randomizing patients to placebo. For example, the FDA's 2019 approval of the gene therapy Zolgensma for spinal muscular atrophy compared treated infants with the natural history of the disease.
Randomization is the process of assigning trial participants to study groups by chance rather than by choice. A computer algorithm typically generates the assignments, and neither participants nor (in most modern trials) the principal investigator can influence which group a person joins. The randomization is usually stratified by key prognostic factors so that the groups are balanced on age, disease severity, prior treatments, and other variables.
Randomization eliminates selection bias. If sicker patients self-selected into the active drug arm, the trial results would be biased and uninterpretable. Randomization ensures that any difference in outcomes between groups can be attributed to the treatment itself, not to differences between the people in each group.
The simplest randomization scheme is parallel-group randomization, where each participant is assigned to one group and stays there for the entire trial. Modern trials sometimes use adaptive randomization, where the assignment ratio shifts during the trial based on early results. Bayesian adaptive designs can give later-enrolling patients better odds of receiving the more promising treatment.
Blinding (also called masking) means that one or more parties involved in a clinical trial do not know which treatment a participant is receiving. Blinding prevents expectations from influencing how participants report symptoms and how clinicians measure outcomes.
In a single-blind trial, the participant does not know which group they are in, but the researcher does. Single-blinding is sometimes used when it is hard to hide the treatment from the care team. The researcher must follow strict protocol-defined assessment criteria to prevent their knowledge from biasing measurements.
In a double-blind trial, neither the participant nor the front-line research team knows the assignment until the trial is unblinded for analysis. Double-blinding is widely considered the strongest way to prevent bias. FDA rules do not require it in every trial, but they do require studies to take adequate steps to reduce bias, and blinding is the usual example.
A triple-blind trial extends blinding to the data analysts and statisticians who interpret the results. It can be used when strong beliefs about the treatment could influence statistical decisions.
When an effective treatment for the condition already exists, withholding it via placebo is often considered unethical. In these cases, trials use an active comparator design instead. The new drug is compared against the current standard-of-care medication, and every participant receives an active treatment.
Active comparator trials answer a different question than placebo-controlled trials. A placebo trial answers whether the drug works at all; an active comparator trial answers whether the new drug works better than (or as well as) the existing standard. Non-inferiority trials are a specific type of active comparator design, structured to demonstrate that the new drug is not meaningfully worse than the standard, often with the goal of offering an alternative that is safer, cheaper, or easier to administer.
As more rare diseases gain approved treatments, trials may compare a new drug with an existing one, or add either the new drug or a placebo on top of current treatment. For example, in the main trial of the sickle cell drug voxelotor, many participants kept taking hydroxyurea while also receiving either voxelotor or a placebo. Voxelotor was withdrawn from the market in 2024 because of safety concerns.
Many trials that include a placebo arm offer an open-label extension (OLE) after the blinded portion ends. In an OLE, every participant (including those who received placebo) gets access to the active drug and continues to be monitored. OLE participation is often a major draw for patients considering placebo-controlled trials.
Crossover designs guarantee active drug exposure for every participant within the main trial itself. In a typical crossover, you might receive 12 weeks of placebo followed by 12 weeks of the active drug (or the reverse), with a washout period in between to clear the first treatment from your system. Crossover designs are most appropriate for chronic, stable conditions where the disease state does not change rapidly during the trial.
Always ask the trial coordinator three questions before signing the informed consent. First, is there a placebo arm and what is the randomization ratio? Second, is there an open-label extension, and do all participants qualify? Third, if the drug works for me, what are my options for continued access after the trial ends? The answers can change your decision substantially.
The Declaration of Helsinki, adopted by the World Medical Association and updated most recently in October 2024, sets the international ethical framework for medical research. Paragraph 33 specifically addresses the use of placebo. The Declaration permits placebo when no proven treatment exists. It also permits placebo when there are strong scientific reasons for it and participants will not face added risk of serious or irreversible harm from not getting the proven treatment.
U.S. rules do not mention placebo directly, but they require an ethics board to find that a study's risks are reasonable compared with its expected benefits and the importance of what it may teach. This applies to federally funded research under 45 CFR 46.111 and to FDA-regulated trials under 21 CFR 56.111. Institutional Review Boards (IRBs) review every trial protocol and must approve the use of placebo before a trial can begin. If a placebo design is approved, the IRB has determined that the scientific value of the trial outweighs the risk of being assigned to placebo.
Patients have the right to ask the trial team about the IRB-approved rationale for using placebo. Federal rules require the consent form to describe the study procedures, point out which ones are experimental, and explain other treatment options outside the trial. If the form does not clearly say why a placebo is used or what your chances are of getting it, ask. If you do not understand the placebo justification, ask for clarification before signing.
A placebo in a clinical trial is a dummy treatment that looks identical to the experimental drug but contains no active ingredient. Common forms include a sugar pill, a saline injection, or a sham device. Placebos are used so that participants and researchers cannot tell which group a person is in, allowing the trial to measure the actual effect of the drug separately from the psychological effect of being treated.
Whether you will receive a placebo depends on the specific trial design. Many rare disease trials are open-label, meaning everyone receives the active drug with no placebo group. Some trials that include placebo give you a higher chance of getting the study drug, such as 2 out of 3, and crossover designs give every participant who completes the trial the study drug at some point. Ask the trial coordinator for the randomization ratio before enrolling.
In a single-blind clinical trial, the participant does not know which group they are in, but the researcher does. In a double-blind trial, neither the participant nor the front-line research team knows the group assignment until the trial is unblinded for analysis. Double-blinding is widely considered the strongest design because it keeps expectations from biasing how outcomes are measured. FDA rules require steps to reduce bias, such as blinding, but do not require double-blinding in every trial.
Randomization in clinical trials is the process of assigning participants to study groups by chance rather than by choice, typically using a computer algorithm. Randomization eliminates selection bias and ensures that any difference in outcomes between groups can be attributed to the treatment itself, not to systematic differences between the people in each group. Many trials use stratified randomization, which helps balance the groups on factors such as age or disease severity.
An open-label trial is a clinical trial in which both the participant and the researcher know which treatment is being given, with no blinding. Open-label trials are common in early-phase rare disease research, in active comparator trials where blinding is impractical, and in open-label extension studies that follow a blinded main trial. Open-label trials provide direct evidence about safety and tolerability but require careful design to manage bias in subjective outcome measurements.
An open-label extension (OLE) study is a continuation of a clinical trial in which all participants (including those who received placebo) gain access to the active drug after the blinded portion ends. OLE studies allow continued safety monitoring, give placebo participants the chance to receive the active drug, and generate long-term efficacy data. Many late-stage rare disease trials build in OLE designs as a key part of the trial structure.
Under the Declaration of Helsinki, placebo is acceptable when no proven treatment exists, or when there are strong scientific reasons for it and participants will not face added risk of serious or irreversible harm from not getting the proven treatment. Every trial protocol must be reviewed and approved by an Institutional Review Board (IRB), which assesses whether the placebo use is justified by the scientific value of the trial.
A crossover clinical trial is a study design in which every participant receives both the active drug and the comparator (placebo or another active drug) at different time points, separated by a washout period that allows the first treatment to clear the body. Crossover designs guarantee active drug exposure for every participant and are most appropriate for chronic, stable conditions where the disease state does not change rapidly during the trial.
Pick it below. One email when a new trial opens, a trial changes or the FDA acts on a treatment. Never a newsletter.